MedTrace Logo

Fat Distribution in Healthy Early Postmenopausal Women

NCT00335218 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2014-12-30

No results posted yet for this study

Summary

The aim of this study is to explore the effects of hormone replacement therapy with EV/DNG on abdominal fat distribution measured by magnetic resonance imaging.

Conditions

  • Healthy
  • Postmenopause

Interventions

DRUG

Climodien / Lafamme (BAY86-5027)

1 tablet daily (2 mg EV + 2 mg DNG)

DRUG

Placebo

1 tablet daily

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
48 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-07-31
Completion
2004-08-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00335218 on ClinicalTrials.gov